Evidence for a positive association between serum carnitine and free testosterone levels in uremic men with hemodialysis

Rejuvenation Research

Volumn 16, Issue 3, 2013, Pages 200-205

  Sakai, Kazuko ^a   Fukami, Kei ^a   Yamagishi, Sho Ichi ^a   Kaida, Yusuke ^a   Adachi, Takeki ^a   Ando, Ryotaro ^a   Manabe, Rie ^a   Otsuka, Aki ^b   Sugi, Kenzo ^b   Ueda, Seiji ^a   Okuda, Seiya ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Sugi Cardiovascular Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; CARNITINE; CREATININE; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PENTOSIDINE; TESTOSTERONE;

ADULT; AGED; ARTICLE; BLOOD CHEMISTRY; CARNITINE DEFICIENCY; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; MALE; PRIORITY JOURNAL; TESTOSTERONE BLOOD LEVEL; UREMIA;

AGED; CARNITINE; HUMANS; MALE; MIDDLE AGED; RENAL DIALYSIS; TESTOSTERONE; UREMIA;

EID: 84879075048     PISSN: 15491684     EISSN: 15578577     Source Type: Journal    
DOI: 10.1089/rej.2012.1399     Document Type: Article

References (40)

1. Carrero JJ, Qureshi AR, Parini P, Arver S, Lindholm B, Bárány P, Heimbü rger O, Stenvinkel P. Low serum testosterone increases mortality risk among male dialysis patients. J Am Soc Nephrol 2009;20:613-620.
2. Iglesias P, Carrero JJ, D?́ez JJ. Gonadal dysfunction in men with chronic kidney disease: Clinical features, prognostic implications and therapeutic options. J Nephrol 2012;25: 31-42.
3. Kyriazis J, Tzanakis I, Stylianou K, Katsipi I, Moisiadis D, Papadaki A, Mavroeidi V, Kagia S, Karkavitsas N, Daphnis E. Low serum testosterone, arterial stiffness and mortality in male haemodialysis patients. Nephrol Dial Transplant 2011;26:2971-2977.
4. Palmer BF. Sexual dysfunction in uremia. J Am Soc Nephrol 1999;10:1381-1388.
5. Chatterjee R, Wood S, McGarrigle HH, Lees WR, Ralph DJ, Neild GH. A novel therapy with testosterone and sildenafil for erectile dysfunction in patients on renal dialysis or after renal transplantation. J Fam Plann Reprod Health Care 2004;30:88-90.
6. Francomano D, Bruzziches R, Natali M, Aversa A, Spera G. Cardiovascular effect of testosterone replacement therapy in aging male. Acta Biomed 2010;81(Suppl 1):101-106.
7. Bøhmer T, Hoel P, Purvis K, Hansson V. Carnitine levels in human accessory sex organs. Arch Androl 1978;1:53-59.
8. Evans AM, Fornasini G. Pharmacokinetics of L-carnitine. Clin Pharmacokinet 2003;42:941-967.
9. Evans A. Dialysis-related carnitine disorder and levocarnitine pharmacology. Am J Kidney Dis 2003;41:S13-S26.
10. Adachi T, Fukami K, Yamagishi S, Kaida Y, Ando R, Sakai K, Adachi H, Otsuka A, Ueda S, Sugi K, Okuda S. Decreased serum carnitine is independently correlated with increased tissue accumulation levels of advanced glycation end products in haemodialysis patients. Nephrology (Carlton) 2012;17:689-694.
11. Cavallini G, Caracciolo S, Vitali G, Modenini F, Biagiotti G. Carnitine versus androgen administration in the treatment of sexual dysfunction, depressed mood, and fatigue associated with male aging. Urology 2004;63:641-646.
12. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988;318:1315-1321.
13. Grandhee SK, Monnier VM. Mechanism of formation of the Maillard protein cross-link pentosidine. Glucose, fructose, and ascorbate as pentosidine precursors. J Biol Chem 1991;266:11649-11653.
14. Dyer DG, Blackledge JA, Thorpe SR, Baynes JW. Formation of pentosidine during nonenzymatic browning of proteins by glucose. Identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo. J Biol Chem 1991;266:11654-11660.
15. Makita Z, Radoff S, Rayfield EJ, Yang Z, Skolnik E, Delaney V, Friedman EA, Cerami A, Vlassara H. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 1991;325:836-842.
16. Vlassara H. Recent progress in advanced glycation end products and diabetic complications. Diabetes 1997;46(Suppl 2):S19-S25.
17. Nakamura T, Sato E, Fujiwara N, Kawagoe Y, Ueda Y, Suzuki T, Yamada S, Takeuchi M, Fukami K, Ueda S, Adachi H, Matsui T, Okuda S, Yamagishi S. Positive association of serum levels of advanced glycation end products and high mobility group box-1 with asymmetric dimethylarginine in nondiabetic chronic kidney disease patients. Metabolism 2009;58:1624-1628.
18. Yamagishi S. Advanced glycation end products and receptor-oxidative stress system in diabetic vascular complications. Ther Apher Dial 2009;13:534-539.
19. Kilhovd BK, Juutilainen A, Lehto S, Ronnemaa T, Torjesen PA, Birkeland KI, Berg TJ, Hanssen KF, Laakso M. High serum levels of advanced glycation end products predict increased coronary heart disease mortality in nondiabetic women but not in nondiabetic men: A population-based 18-year follow-up study. Arterioscler Thromb Vasc Biol 2005; 25:815-820.
20. Kilhovd BK, Juutilainen A, Lehto S, Ronnemaa T, Torjesen PA, Hanssen KF, Laakso M. Increased serum levels of advanced glycation endproducts predict total, cardiovascular and coronary mortality in women with type 2 diabetes: A population-based 18 year follow-up study. Diabetologia 2007;50:1409-1417.
21. Furuya R, Kumagai H, Miyata T, Fukasawa H, Isobe S, Kinoshita N, Hishida A. High plasma pentosidine level is accompanied with cardiovascular events in hemodialysis patients. Clin Exp Nephrol 2011;16:421-426.
22. Jiaan DB, Seftel AD, Fogarty J, Hampel N, Cruz W, Pomerantz J, Zuik M, Monnier VM. Age-related increase in an advanced glycation end product in penile tissue. World J Urol 1995;13:369-375.
23. Usta MF, Bivalacqua TJ, Yang DY, Ramanitharan A, Sell DR, Viswanathan A, Monnier VM, Hellstrom WJ. The protective effect of aminoguanidine on erectile function in streptozotocin diabetic rats. J Urol 2003;170:1437-1442.
24. Usta MF, Kendirci M, Gur S, Foxwell NA, Bivalacqua TJ, Cellek S, Hellstrom WJ. The breakdown of preformed advanced glycation end products reverses erectile dysfunction in streptozotocin-induced diabetic rats: Preventive versus curative treatment. J Sex Med 2006;3:242-250.
25. Ishibashi Y, Matsui T, Takeuchi M, Yamagishi S. Vardenafil, an inhibitor of phosphodiesterase-5, blocks advanced glycation end product (AGE)-induced up-regulation of monocyte chemoattractant protein-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression via elevation of cGMP. Clin Exp Med 2011;11:131-135.
26. Tahara N, Imaizumi T, Takeuchi M, Yamagishi SI. Insulin resistance is an independent correlate of high serum levels of advanced glycation end products (AGEs) and low testosterone in non-diabetic men. Oxid Med Cell Longev 2010;3:262-265.
27. Takahashi M, Ueda S, Misaki H, Sugiyama N, Matsumoto K, Matsuo N, Murao S. Carnitine determination by an enzymatic cycling method with carnitine dehydrogenase. Clin Chem 1994;40:817-821.
28. Sanaka T, Funaki T, Tanaka T, Hoshi S, Niwayama J, Taitoh T, Nishimura H, Higuchi C. Plasma pentosidine levels measured by a newly developed method using ELISA in patients with chronic renal failure. Nephron 2002;91:64-73.
29. Nagano M, Fukami K, Yamagishi S, Sakai K, Kaida Y, Matsumoto T, Hazama T, Tanaka M, Ueda S, Okuda S. Tissue level of advanced glycation end products is an independent determinant of high-sensitivity C-reactive protein levels in haemodialysis patients. Nephrology (Carlton) 2011;16:299-303.
30. Daugirdas JT. Linear estimates of variable-volume, singlepool Kt/V: An analysis of error. Am J Kidney Dis 1993;22: 267-270.
31. Gentile V, Vicini P, Prigiotti G, Koverech A, Di Silverio F. Preliminary observations on the use of propionyl-L-carnitine in combination with sildenafil in patients with erectile dysfunction and diabetes. Curr Med Res Opin 2004;20:1377-1384.
32. Cavallini G, Modenini F, Vitali G, Koverech A. Acetyl-Lcarnitine plus propionyl-L-carnitine improve efficacy of sildenafil in treatment of erectile dysfunction after bilateral nerve-sparing radical retropubic prostatectomy. Urology 2005;66:1080-1085.
33. Sayed-Ahmed MM, Khattab MM, Gad MZ, Mostafa N. L-carnitine prevents the progression of atherosclerotic lesions in hypercholesterolaemic rabbits. Pharmacol Res 2001;44: 235-242.
34. Shankar SS, Mirzamohammadi B, Walsh JP, Steinberg HO. L-carnitine may attenuate free fatty acid-induced endothelial dysfunction. Ann NY Acad Sci 2004;1033:189-197.
35. Salvioli G, Neri M. L-acetylcarnitine treatment of mental decline in the elderly. Drugs Exp Clin Res 1994;20:169-176.
36. Palmero S, Leone M, Prati M, Costa M, Messeni Leone M, Fugassa E, De Cecco L. The effect of L-acetylcarnitine on some reproductive functions in the oligoasthenospermic rat. Horm Metab Res 1990;22:622-626.
37. Bidzinska B, Petraglia F, Angioni S, Genazzani AD, Criscuolo M, Ficarra G, Gallinelli A, Trentini GP, Genazzani AR. Effect of different chronic intermittent stressors and acetyl-Lcarnitine on hypothalamic beta-endorphin and GnRH and on plasma testosterone levels in male rats. Neuroendocrinology 1993;57:985-990.
38. Rajasekar P, Anuradha CV. L-Carnitine inhibits protein glycation in vitro and in vivo: Evidence for a role in diabetic management. Acta Diabetol 2007;44:83-90.
39. Herzog AG, Levesque LA. Testosterone, free testosterone, non-sex hormone-binding globulin-bound testosterone, and free androgen index: Which testosterone measurement is most relevant to reproductive and sexual function in men with epilepsy? Arch Neurol 1992;49:133-135.
40. Corona G, Boddi V, Balercia G, Rastrelli G, De Vita G, Sforza A, Forti G, Mannucci E, Maggi M. The effect of statin therapy on testosterone levels in subjects consulting for erectile dysfunction. J Sex Med 2010;7:1547-1556.